Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bactiguard Holding AB (publ) (BACTI-B.ST)
Tullinge, SE
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.52% | +0.98% | -15.99% | -10.92% | -6.63% | -18.42% | -55.71% | -79.03% | -91.90% | +16.10% | -50.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-11.4% Q1'26: -28.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+74.1% ★ Q1'26: -23.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+2.8% Q1'26: -19.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-0.9% Q1'26: -14.1% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-0.5% Q1'26: -3.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.61× Q1'26: 7.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
131.42M
est: 142.40M (-7.7%)
|
118.74M
est: 120.54M (-1.5%)
|
147.46M
est: 140.94M (+4.6%)
|
150.10M
est: 165.64M (-9.4%)
|
184.99M
est: 184.82M (+0.1%)
|
172.32M
est: 182.17M (-5.4%)
|
169.49M
est: 181.86M (-6.8%)
|
223.56M
est: 242.99M (-8.0%)
|
203.99M
est: 213.05M (-4.3%)
|
243.68M
est: 254.19M (-4.1%)
|
215.92M
est: 209.00M (+3.3%)
|
208.50M
208.50M – 208.50M
-0.2% YoY
|
239.17M
239.17M – 239.17M
+14.7% YoY
|
266.00M
257.50M – 274.50M
+11.2% YoY
|
| EBITDA |
21.10M
est: -9.38M (+324.9%)
|
17.28M
est: -7.94M (+317.6%)
|
33.16M
est: -9.28M (+457.3%)
|
19.54M
est: -10.91M (+279.2%)
|
59.12M
est: -12.17M (+585.7%)
|
8.05M
est: -12.00M (+167.1%)
|
-5.94M
est: -11.98M (+50.4%)
|
-543.0K
est: -16.00M (+96.6%)
|
-89.98M
est: -14.03M (-541.3%)
|
24.99M
est: -8.49M (+394.4%)
|
45.15M
est: -6.98M (+747.0%)
|
-6.96M
-6.96M – -6.96M
+0.2% YoY
|
-7.99M
-7.99M – -7.99M
-14.7% YoY
|
-8.88M
-9.16M – -8.60M
-11.2% YoY
|
| EBIT |
-11.83M
est: -41.93M (+71.8%)
|
-16.10M
est: -35.49M (+54.6%)
|
-1.85M
est: -41.50M (+95.5%)
|
-12.71M
est: -48.77M (+73.9%)
|
19.66M
est: -54.42M (+136.1%)
|
-33.12M
est: -53.64M (+38.2%)
|
-54.88M
est: -53.55M (-2.5%)
|
-51.16M
est: -71.55M (+28.5%)
|
-133.63M
est: -62.73M (-113.0%)
|
-21.90M
est: -65.52M (+66.6%)
|
-1.93M
est: -53.87M (+96.4%)
|
-53.75M
-53.75M – -53.75M
+0.2% YoY
|
-61.65M
-61.65M – -61.65M
-14.7% YoY
|
-68.57M
-70.76M – -66.38M
-11.2% YoY
|
| Net Income |
-26.50M
est: -56.98M (+53.5%)
|
-26.85M
est: -25.58M (-5.0%)
|
-3.25M
est: -11.21M (+71.0%)
|
-14.93M
est: 2.28M (-755.5%)
|
16.26M
est: 39.60M (-58.9%)
|
-38.39M
est: 2.80M (-1,469.3%)
|
-58.77M
est: -22.78M (-158.0%)
|
-52.88M
est: -29.44M (-79.6%)
|
-138.38M
est: -103.73M (-33.4%)
|
-29.82M
est: -16.47M (-81.0%)
|
-7.84M
est: -7.18M (-9.2%)
|
350.4K
350.4K – 350.4K
+104.9% YoY
|
17.35M
17.35M – 17.35M
+4,850.0% YoY
|
36.10M
36.10M – 36.10M
+108.1% YoY
|
| SGA |
56.29M
est: 30.86M (+82.4%)
|
46.70M
est: 26.12M (+78.8%)
|
42.33M
est: 30.55M (+38.6%)
|
56.43M
est: 35.90M (+57.2%)
|
43.51M
est: 40.06M (+8.6%)
|
49.33M
est: 39.48M (+24.9%)
|
56.10M
est: 39.41M (+42.3%)
|
83.23M
est: 52.66M (+58.0%)
|
19.18M
est: 46.17M (-58.5%)
|
—
est: 40.53M (-100.0%)
|
—
est: 33.33M (-100.0%)
|
33.25M
33.25M – 33.25M
-0.2% YoY
|
38.14M
38.14M – 38.14M
+14.7% YoY
|
42.42M
41.06M – 43.77M
+11.2% YoY
|
| EPS |
-0.80
est: -1.63 (+50.8%)
|
-0.81
est: -0.73 (-11.0%)
|
-0.10
est: -0.32 (+69.5%)
|
-0.45
est: 0.07 (-792.3%)
|
0.49
est: 1.13 (-56.6%)
|
-1.14
est: 0.08 (-1,525.0%)
|
-1.68
est: -0.65 (-158.5%)
|
-1.51
est: -0.84 (-79.8%)
|
-3.95
est: -2.96 (-33.4%)
|
-0.85
est: -0.47 (-80.9%)
|
-0.22
est: -0.21 (-7.3%)
|
0.01
0.01 – 0.01
+104.9% YoY
|
0.50
0.50 – 0.50
+4,850.0% YoY
|
1.03
1.03 – 1.03
+108.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alf Laurell | Executive Vice President of Regulatory & Quality | — | male |
| Christine Lind | Chief Executive Officer | — | female |
| Ian S. E. N. Christensen | Senior Vice President of Wound Management | — | male |
| Kajsa Bjorklund | Executive Vice President of Research & Development | — | female |
| Mattias Thorsson | Executive Vice President of Communications | — | male |
| Nathaniel Bachrach | Chief Scientific Officer | — | — |
| Patrick Bach | Chief Financial Officer | — | male |
| Sophie Dahan | Executive Vice President of Business Development & Alliance Management | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BACTI-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
